177Lu-DOTA-Miltuximab

N/A

Report date: 2025/11/21 17:16:25

Base Information

Drug Name177Lu-DOTA-Miltuximab

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agent +[6]

Mechanisms of ActionSingle-photon emission-computed tomography enhancersGlypican-1 antagonistsWnt signalling pathway inhibitors

TargetsGlypican-1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesGlytherix

China Registration ClassN/A

Develop Information

Active CompaniesGlytherix

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A